Internal Medicine, Endocrinology, Diabetes, & Metabolism · Thibodaux, LA
NPI
1932337052
Since 2009
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
726 N Acadia Rd., Ste 3300
Thibodaux, LA, 70301
Phone (985) 493-3080
Groups this clinician bills Medicare through
Medicare paid, 2024
$101K
1,883 services
Medicare patients, 2024
632
Average age 72
Drug cost, 2024
$8.0M
13,268 prescriptions
Company payments, 2025
$29K
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Lane M Frey was code 99214 (office e&m - established), 910 times for 534 patients. In total Lane M Frey billed 1,883 services in 12 codes, and Medicare paid $101K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-07-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 910 | 534 | $84.85 | $77K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 799 | 485 | $11.83 | $9,455 |
| 99204 Office E&M - New | Office | 86 | 86 | $113.16 | $9,732 |
| 99213 Office E&M - Established | Office | 47 | 42 | $53.28 | $2,504 |
By year: 2022 $96K for 1,195 services; 2023 $97K for 1,176 services; 2024 $101K for 1,883 services.
Medicare prescription drug claims, 2024
In 2024, the drug Lane M Frey prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,719 prescriptions and refills. In total Lane M Frey wrote 13,268 Medicare prescriptions that cost $8.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,719 | 4,456 | 416 | $18K |
| Ozempic Semaglutide | 1,296 | 2,384 | 306 | $2.3M |
| Jardiance Empagliflozin | 1,280 | 2,421 | 288 | $1.4M |
| Metformin Hcl Generic | 853 | 2,209 | 239 | $5,729 |
| Metformin Hcl Er Metformin Hcl | 602 | 1,568 | 177 | $6,548 |
| Pioglitazone Hcl Generic | 531 | 1,320 | 138 | $6,088 |
| Trulicity Dulaglutide | 472 | 816 | 116 | $798K |
| Glipizide Er Glipizide | 470 | 1,219 | 149 | $4,352 |
| Mounjaro Tirzepatide | 399 | 697 | 95 | $772K |
| Tresiba Flextouch U-200 Insulin Degludec | 397 | 984 | 130 | $378K |
| Synthroid Levothyroxine Sodium | 363 | 836 | 90 | $28K |
| Farxiga Dapagliflozin Propanediol | 343 | 611 | 80 | $336K |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 313 | 685 | 82 | $358K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 292 | 727 | 113 | $28K |
| Novolog Flexpen Insulin Aspart | 215 | 472 | 71 | $64K |
Brand drugs: 7,505 claims; generic drugs: 5,055 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Lane M Frey $29K ($29K in general payments such as food, travel and fees) from 23 companies. The largest payer was Novo Nordisk Inc with $28K.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 30 | $28K |
| Amgen Inc. AMGN | 9 | $211 |
| Beta Bionics, Inc. BBNX | 4 | $84.21 |
| Lilly USA, LLC LLY | 3 | $60.39 |
| Tandem Diabetes Care, Inc. TNDM | 2 | $53.11 |
| Abbvie Inc. ABBV | 3 | $46.98 |
| Ascendis Pharma Endocrinology Inc ASND | 2 | $45.22 |
| Sanofi-Aventis U.S. LLC SNY | 2 | $44.15 |
| Xeris Pharmaceuticals, Inc. | 2 | $42.5 |
| Insulet Corporation PODD | 2 | $42.34 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.